Tags : patients

Regulatory

Janssen’s Darzalex (daratumumab, SC) Combination Regimen Receives Health Canada’s Approval

Shots: The approval is based on results from the P-III ANDROMEDA (AMY3001) study involves assessing the safety and efficacy of Darzalex (1800mg, SC, qw) + bortezomib, cyclophosphamide, and dexamethasone (VCd) vs VCd alone in 388 patients with newly diagnosed AL amyloidosis The study showed higher hematologic response rate in ITT population (53% vs 18%), patients […]Read More

Clinical Trials

Zogenix Presents Results of Fintepla’s (fenfluramine) Study Highlighting the Impact

Shots: The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families Results: seizure-related benefits noted by caregivers include a reduction in frequency, seizure activity, and shorter recovery time while non-seizure benefits include improvements in executive functions […]Read More